Načítá se...

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

Myeloproliferative neoplasm (MPN) transformed to acute myeloid leukemia (MPN-AML), MPN in accelerated phase (MPN-AP), and high-risk primary myelofibrosis (PMF) are associated with a poor response to therapy and very short survival. Several reports have suggested clinical activity of hypomethylating...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res
Hlavní autoři: Badar, Talha, Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Cortes, Jorge E., Pemmaraju, Naveen, Pierce, Sherry R., Newberry, Kate J., Daver, Naval, Verstovsek, Srdan
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546869/
https://ncbi.nlm.nih.gov/pubmed/26183878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.06.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!